Zenas BioPharma, Inc. - 8-K Filing
Zenas BioPharma reported Q1 2026 financial results with cash balances of $718.5M and R&D expenses of $60.4M (up from $34.9M in Q1 2025). The company raised $419M through public offerings, debt financing, and ATM sales since January 2026. It also announced key clinical updates: obexelimab Phase 3 INDIGO trial results accepted for EULAR presentation; SunStone SLE enrollment complete with topline data expected in Q4 2026; ZB021 Phase 1 dosing began, and PriMroSe/naSPMS trials ongoing. Director Tomas Kiselak resigned after not seeking re-election at the May 11 annual meeting. (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $ZBIO